Massachusetts Financial Services Co. MA Grows Position in Kenvue Inc. (NYSE:KVUE)

Massachusetts Financial Services Co. MA grew its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 12.3% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 97,661,344 shares of the company's stock after acquiring an additional 10,682,003 shares during the period. Massachusetts Financial Services Co. MA owned about 5.09% of Kenvue worth $2,085,070,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock worth $4,665,908,000 after purchasing an additional 1,636,741 shares during the period. State Street Corp boosted its position in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock worth $980,989,000 after buying an additional 1,391,854 shares during the last quarter. Franklin Resources Inc. increased its position in Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after buying an additional 16,269,721 shares in the last quarter. Finally, Harris Associates L P increased its position in Kenvue by 7.5% during the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company's stock valued at $727,658,000 after buying an additional 2,186,114 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Remove Ads

Kenvue Stock Performance

Shares of KVUE stock traded down $0.23 on Thursday, reaching $23.65. The stock had a trading volume of 21,703,204 shares, compared to its average volume of 16,767,870. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a market cap of $45.19 billion, a P/E ratio of 44.61, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a 50 day simple moving average of $22.56 and a 200 day simple moving average of $22.48.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.47%. Kenvue's dividend payout ratio (DPR) is 154.72%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Canaccord Genuity Group increased their target price on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and decreased their target price for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Barclays boosted their price objective on shares of Kenvue from $21.00 to $23.00 and gave the stock an "equal weight" rating in a report on Thursday, March 27th. Finally, Citigroup lowered their price objective on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $24.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.